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Abstract 
Background: NSC260594, a quinolinium derivative from the NCI diversity set II compound library, was previously 
identified in a target-based assay as an inhibitor of the interaction between the HIV-1 (ψ) stem-loop 3 (SL3) RNA and 
Gag. This compound was shown to exhibit potent antiviral activity. Here, the effects of this compound on individual 
stages of the viral lifecycle were examined by qRT-PCR, ELISA and Western blot, to see if its actions were specific to the 
viral packaging stage. The structural effects of NSC260594 binding to the HIV-1 gRNA were also examined by SHAPE 
and dimerization assays.
Results: Treatment of cells with NSC260594 did not reduce the number of integration events of incoming virus, and 
treatment of virus producing cells did not affect the level of intracellular Gag protein or viral particle release as deter-
mined by immunoblot. However, NSC260594 reduced the incorporation of gRNA into virions by up to 82%, without 
affecting levels of gRNA inside the cell. This reduction in packaging correlated closely with the reduction in infectiv-
ity of the released viral particles. To establish the structural effects of NSC260594 on the HIV-1 gRNA, we performed 
SHAPE analyses to pinpoint RNA structural changes. NSC260594 had a stabilizing effect on the wild type RNA that was 
not confined to SL3, but that was propagated across the structure. A packaging mutant lacking SL3 did not show this 
effect.
Conclusions: NSC260594 acts as a specific inhibitor of HIV-1 RNA packaging. No other viral functions are affected. Its 
action involves preventing the interaction of Gag with SL3 by stabilizing this small RNA stem-loop which then leads to 
stabilization of the global packaging signal region (psi or ψ). This confirms data, previously only shown in analyses of 
isolated SL3 oligonucleotides, that SL3 is structurally labile in the presence of Gag and that this is critical for the com-
plete psi region to be able to adopt different conformations. Since replication is otherwise unaffected by NSC260594 
the flexibility of SL3 appears to be a unique requirement for genome encapsidation and identifies this process as a 
highly specific drug target. This study is proof of principle that development of a new class of antiretroviral drugs that 
specifically target viral packaging by binding to the viral genomic RNA is achievable.
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Background
For HIV there is now a range of effective drugs targeting 
different stages of viral replication yet mutational escape 
from all of these has been achieved by the virus. Between 
the stages of integration of the provirus and virion matu-
ration however there is a therapeutic gap wherein many 
of the processes are not virus specific. Exceptions include 
compounds targeting viral assembly binding to the 
HIV-1 Gag protein, or its NC domain, and interfering 
with genome encapsidation or virion maturation [1–3]. 
Others work by destabilizing and ejecting zinc from the 
two zinc knuckles in the NC domain. Almost all of them 
target the viral protein [4, 5].
The HIV-1 5′UTR is around 330 nucleotides (nt) long 
and contains a series of overlapping cis-acting signals that 
interact with viral and cellular factors to control the viral 
lifecycle. It is far more highly conserved than the coding 
regions that follow it, with little or no variation observed 
between hundreds of sequenced clinical isolates in some 
sections [6]. This degree of conservation against the 
background of a high viral mutation rate indicates the 
essential nature of these sequences, the structures they 
subtend and the inability of the virus to tolerate muta-
tion within them. Compounds that target the Gag-RNA 
interaction by binding to highly conserved sequences of 
the RNA instead of the cognate protein may provide far 
less scope for mutational escape. One such region that 
shows extremely limited variation is a 14 nt stretch just 
upstream of the Gag translation initiation site. This RNA 
folds into a stable helix known as SL3, which has been 
shown to be of importance during the viral packaging 
process, by specifically binding the Gag protein in a high-
affinity interaction [7, 8].
NSC260594 (hereafter referred to as NSC) is a quino-
linium derivative that we identified in a high-throughput 
screen for compounds that interfere with the interac-
tion between SL3 and Gag [9]. By NMR analysis this 
compound was shown to bind specifically to the termi-
nal loop of SL3 where Gag is known to interact. NSC 
was also shown to inhibit production of infectious HIV 
in vitro at micromolar concentrations. The SL3 sequence 
has few predicted counterparts in the human genome, 
and the compound displays low cytotoxicity. This sug-
gested that within infected cells its effect is related to it 
inhibiting genome encapsidation although this was not 
formally shown.
However, despite circumstantial evidence that NSC 
binds to SL3 and interferes with Gag binding in  vitro, 
the HIV-1 5′UTR contains multiple cis- and trans-acting 
functions, including other protein binding sites and there 
is evidence that it undergoes a range of conformational 
changes in order to facilitate viral replication [10]. It is 
therefore possible that a compound that binds to SL3 
exerts its antiviral effects at other and/or multiple stages 
of the HIV lifecycle. NSC has also been shown in a recent 
screen to be a protein binding inhibitor of the dengue 
virus 2 protease [11].
To clarify the true effect of NSC in a replicating viral 
system and to attempt to validate the potential for devel-
opment of RNA targeting antiretrovirals, and antipackag-
ing inhibitors, we examined the specific role of NSC in 
inhibiting multiple stages of the HIV-1 lifecycle. We show 
that NSC specifically targets the viral packaging process, 
resulting in significantly lower presence of genomic viral 
RNA inside the virions. It does not affect the steady state 
levels of viral unspliced genomic RNA (gRNA) or Gag 
protein inside cells. It does not interfere with viral reverse 
transcription or integration. When assessed by immuno-
blot we find that NSC does not significantly reduce viral 
particle production.
To further evaluate the mechanism by which NSC 
interferes with gRNA encapsidation the structural 
changes induced by NSC binding to the viral leader were 
studied by SHAPE chemistry. We show that NSC bind-
ing to SL3 has effects on several parts of the leader RNA, 
including SL3 itself. These changes were not observed 
when NSC was incubated with an SL3 deleted RNA. 
These findings suggest that NSC disrupts the interaction 
of SL3 with Gag but also, through stabilizing SL3, it leads 
to reduced conformational flexibility of the wider back-
bone structure of the RNA in the 5′leader. These obser-
vations reveal the critical nature of structural change in 
the RNA during the encapsidation process and provide 
proof-of-principle that specific RNA-targeting anti-pack-
aging compounds are an achievable therapeutic aim.
Methods
Reagents
NSC260594 (Benzamide, 4-[(1-methyl-6-nitro-4(1H)-
quinolinylidene)amino]-N-[4-[(1-methyl-4(1H)-pyridi-
nylidene)amino]phenyl]-, molecular weight 505.0) was 
supplied by NCI-DTP (www.dtp.cancer.gov). It was dis-
solved in DMSO at 20 mM and stored at − 20  °C. Plas-
mids pSVC21ΔBglII [12] pSVC21ΔBglIIΔp1 [13, 14] 
pVSVG [15] and pBluescript were grown in E. coli DH5α 
strain and purified using Maxiprep columns (Qiagen), 
and used to produce HIVΔEnv (WT) and HIVΔEnvΔpI 
(ΔpI) viruses. The ΔpI mutation is a 19-nt deletion of the 
SL3 region. Jurkat cells were maintained in RPMI 1640 
medium (Gibco, Life Technologies) supplemented with 
10% fetal bovine serum (Gibco, Life Technologies), peni-
cillin [100  U/ml] and streptomycin [100  µg/ml] (Gibco, 
Life Technologies). 293T and TZMbl cells were main-
tained in DMEM containing 10% (v/v) FCS, 100  U/mL 
penicillin and 100  μg/mL streptomycin (w/v). TZMbl is 
a reporter cell line derived from HeLa cells expressing 
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CXCR4, engineered to express CD4 and CCR5 [16], 
the firefly luciferase gene and the E. coli β-galactosidase 
gene under the control of the HIV-1 LTR [16, 17]. It was 
obtained from the NIH AIDS Research and Reference 
Reagent Program. Full-length LAI virus was produced 
by transfection of pLAI, an infectious molecular clone of 
HIV-1 LAI, into 293T cells for 48 h and the supernatant 
harvested and cleared of cell debris by centrifugation at 
3488×g for 5 min. An LAI plasmid-free virus stock was 
produced by infecting Jurkat cells with virus-containing 
supernatant followed by serial passaging in Jurkat cells. 
The LAI containing supernatant was cleared of cell debris 
by centrifugation at 2671×g for 5 min prior to the inte-
gration assay described below.
qRT‑PCR to measure intracellular and extracellular HIV RNA 
levels
293T cells were plated 24  h before transfection in six-
well plates at a density of  106 cells/well. Transfections 
were performed with TransIT-LT1 (Mirus) using 150 ng 
of either pSVC21ΔBglII or pSVC21ΔBglIIΔp1 and 50 ng 
of pVSVG and following manufacturer’s instructions. 
pBluescript up to 1 μg was added to all wells as a bulk-
ing agent for transfection and to ensure even amounts of 
DNA were added to each well. 6 h post transfection cells 
were treated with NSC dissolved in DMSO to a final con-
centration of 50 μM or an equal volume of DMSO only. 
24 h post treatment, supernatants and cellular fractions 
were collected. RNA was extracted from cells using the 
Qiagen RNeasy kit according to manufacturer’s instruc-
tions, but without DNase treatment on the columns. 
DNA was subsequently removed by DNase treatment of a 
smaller volume of the purified nucleic acid with TURBO 
DNase (Thermo Fisher Scientific) in DNase buffer for 2 h 
at 37 °C and the RNA was recovered with phenol–chloro-
form extraction and ethanol precipitation. Supernatants 
were harvested for purification of RNA from virions. Ini-
tially supernatants were clarified at 5600×g for 10 min to 
pellet cell debris. Virions were then purified by centrifug-
ing a 2:1 ratio of supernatant: 8.4% Optiprep in PBS at 
21,500×g for 90  min. Virions were resuspended in 10% 
of the original supernatant volume of PBS followed by 
the addition of 10× that volume of Proteinase K buffer 
(50 mM Tris–Cl pH 7.5, 100 mM NaCl, 10 mM EDTA, 
1% SDS, 100 μg/ml proteinase K, 100 μg/ml yeast tRNA) 
and incubation for 30 min at 37 °C. RNA was recovered 
with phenol–chloroform extraction and ethanol precipi-
tation, resuspended in 1× DNase buffer and treated with 
1/10th volume of TURBODNase (Thermo Fisher Scien-
tific) for 60  min at 37  °C, phenol–chloroform extracted 
and ethanol precipitated once more and resuspended in 
water.
Cytoplasmic RNA extraction
293T cells were transfected and treated with NSC as 
described above. Cytoplasmic RNA was extracted with 
the RNeasy Mini kit (Qiagen) following the manufactur-
er’s supplementary protocol with minor modifications. In 
brief, 24 h post-NSC treatment, 293T cells were washed 
in PBS followed by cell lysis with 175  µl chilled RLN 
buffer (50  mM Tris–Cl, pH8, 140  mM NaCl, 1.5  mM 
 MgCl2, 0.5% NP-40 (v/v)). Cells were removed by scrap-
ing and incubated on ice for 5 min, followed by centrifu-
gation for 2 min at 300×g. The supernatant was removed 
and mixed with 600  µl RLT buffer (Qiagen), followed 
by incubation for 15  min at room temperature then 
vortexed. Samples were temporarily stored at − 80  °C, 
and 430  µl 96–100% ethanol was added to each sample 
prior to loading of samples onto RNeasy spin columns 
according to the manufacturer’s instructions without on-
column DNase digestion. The RNA was eluted twice in 
30  µl nuclease free  H20. Extracted RNA was subjected 
to DNase treatment with the Turbo DNA-free™ Kit 
(Thermo Fisher Scientific). In brief, 1 µg RNA was treated 
with 1  µl TURBO DNase in 5  µl 10× TURBO DNase 
Buffer in a total volume of 50  µl for 1  h at 37  °C. After 
1  h, 5  µl DNase inactivation reagent was added to each 
reaction and incubated at room temperature for 5  min. 
The reactions were spun at 10,000×g for 1.5 min and the 
supernatant containing DNase-treated RNA was trans-
ferred to a fresh tube.
HIV gag qRT‑PCR
DNase-treated RNA was reverse transcribed with 
the High Capacity cDNA Reverse Transcription Kit 
(Thermo Fisher Scientific) according to the manufac-
turer’s instructions with RNase inhibitor added to the 
reaction, or with the addition of  RNasin® Ribonuclease 
Inhibitor (Promega). The PCR cycling conditions were; 
25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min fol-
lowed by a holding step at 4  °C. The cDNA was further 
diluted to 1–4  ng and subjected to HIV gag qPCR with 
25–50 nM HIV gag forward primer; HIV gag 6F: 5′-CAT-
GTTTTCAGCATTATCAGAAGGA-3′, and 25–50  nM 
HIV gag reverse primer; HIV gag 84R: 5′-TGCTT-
GATGTCCCCCCACT-3′ and 100  nM HIV gag probe: 
5′-[6FAM]CCACCCCACAAGATTTAAACACCATGCT
AA[BHQ1]-3′ (Sigma) [18] in a reaction buffer contain-
ing 2× Taqman Fast Advanced Master Mix, (Thermo 
Fisher Scientific). The HIV gag qPCR conditions were 
as follows: Step 1. 50 °C for 2 min. Step 2, 95 °C for 20 s. 
Step 3. 95 °C, 3 s followed by 60 °C for 30 s, for 40 cycles.
To determine the relative amounts of HIV gRNA 
and β-actin in each intracellular sample, Ct values were 
interpreted against standard curves generated on the 
same qRT-PCR plate under the same conditions, using 
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known quantities of β-actin standard DNA template 
reagents (401970 TaqMan, Thermo Fisher Scientific) 
or pSVC21ΔBglII. The β-actin primer sequences and 
qPCR cycling conditions are described below. β-Actin 
cDNA template concentrations were in the range of 
500 pg–4 ng. Intracellular HIV-1 gRNA levels were then 
normalized against the β-actin RNA level in each sample 
versus the average β-actin level found in WT samples, 
using the following formula: average β-actin level of WT 
samples/β-actin level of sample. This value was then used 
to multiply the HIV gRNA content of each sample. The 
HIV gRNA value of each extracellular sample was then 
divided by the normalized HIV gRNA level in the corre-
sponding intracellular sample. Outliers were defined as 
values > the value of the third quartile plus 1.5× the inter-
quartile range, or < the value of the first quartile minus 
1.5× the interquartile range [19] 8% of values, evenly 
distributed between WT, NSC and Δp1 samples, fell into 
this range and were excluded from further analyses. All 
data are presented as levels relative to the wild-type aver-
age, which was set to 1.
Western blots
293T cells were transfected and treated with NSC as 
above. Supernatants were removed and clarified to 
remove cellular debris at 16,000×g for 2 min. Viral par-
ticles were inactivated with 0.1% Empigen for 30  min 
at 56  °C and supernatants were stored at − 80  °C. Cells 
were washed with PBS and lysed with 500 μL 1× CCLR 
(cell culture lysis reagent, Promega) for 15 min with gen-
tle rocking, transferred to microfuge tubes and clarified 
at 13,800×g for 1 min before storage at − 80 °C. Samples 
were denatured at 95 °C for 5 min in a 1:1 (v/v) ratio of 
Laemmli loading buffer (Biorad) containing 710  mM 
2-mercaptoethanol and loaded onto SDS-PAGE gradient 
gels (Biorad). Gels were electrophoresed at 180 V for 1 h 
and transferred to nitrocellulose membranes for 20 min 
at 15  V using Biorad semi-dry transfer apparatus and 
Towbin transfer buffer (25  mM Tris, 192  mM glycine, 
20% (v/v) methanol, pH 8.3). Membranes were blocked 
in PBST (PBS with 0.05% Tween-20) and 5% (w/v) non-
fat milk powder for 30  min at room temperature and 
incubated with monoclonal anti-Gag p55/p24 (ARP 313, 
CFAR) in 2.5% (w/v) nonfat milk powder in PBST over-
night at 4  °C. Membranes were washed for 4 × 10  min 
with PBST and incubated with secondary antibody, 
anti-mouse HRP antibody, (Cell Signalling Technology) 
for 30–60  min at room temperature, before washing 
with PBST and PBS and developing with ECL reagent 
(Thermo Fisher Scientific) according to the manufactur-
er’s instructions. Bands were quantitated using Image J 
analysis. Intracellular Gag levels were normalized against 
GAPDH levels by stripping and reprobing the same blots 
with anti-GAPDH antibody (Abcam).
Gag p24 ELISA
96-well microplates (white, half-area, high binding, 
Greiner Bio-One) were coated overnight with 25  µl of 
10 µg/ml anti-HIV-1 p24 Gag antibody (D7320, Aalto Bio 
Reagents) in 0.1 M  NaHCO3. The following day, the coat-
ing antibody was removed and plates were blocked for 
1 h in 5% Bovine Serum Albumin (Sigma-Aldrich) in 1× 
TBS, and then washed four times in 1× TBS. Plates were 
loaded with 25  µl of inactivated sample and a standard 
curve of HIV-1 p24 antigen (AG6054, Aalto Bioreagents), 
ranging from 0.1 to 10 ng/ml, diluted in 0.05% Empigen-
TBS and incubated for 1.5 h. Plates were washed in TBS 
as above and incubated with anti-HIV-1-p24 alkaline 
phosphatase conjugate (BC1071-AP) (Aalto Bioreagents) 
diluted 1:16,000 in 2% milk, 20% sheep serum (Sigma) 
0.05% Tween-20 in 1× TBS for 1 h. Plates were washed 
4× in PBS-0.1% Tween 20 and incubated with Lumiphos 
Plus (Lumigen) for 30  min in the dark. Luminescence 
levels were measured on a GloMax Multi + Multimode 
Reader instrument (Promega).
Infectivity assay
To measure infectivity, 6 × 104 TZMbl cells were plated 
per well in 24-well plates. The following day, 70  µl of 
virus-containing medium, or medium only, was mixed 
with 12.5 µl DEAE dextran (50 µg/µl) and added to each 
well containing TZMbl cells in a total volume of 500 µl 
DMEM containing 10% (v/v) FCS, 100  U/ml penicil-
lin and 100  μg/ml streptomycin (w/v). 24-h post-trans-
duction, the cells were lysed in 150  µl 1× CCLR buffer 
(cell culture lysis reagent, Promega) for 15 min at room-
temperature. 5 µl of cell lysates was added to a white, half 
area, medium binding, 96-well microplate (Grainer Bio-
One) and 25  µl of Luciferase Assay Reagent (Promega) 
was added through injectors with a GloMax Multi + Mul-
timode Reader instrument (Promega) and luminescence 
levels were measured with the following settings; 0.5  s 
delay, speed 100 µl/s and a 2 s integration time. The aver-
age background reading from control cells transduced 
with medium only was subtracted from the reading from 
each experimental sample. These background values were 
less than 2% of the value of the experimental readings. 
Data were normalized to the average of the wild-type in 
each independent experiment.
Integration assay
Jurkat cells were prepared to a density of 5 × 105 cells/
well in 24-well plates on day 1 in 500  µl medium. On 
day 2, Jurkat cells were pre-treated with NSC or ralte-
gravir (NIH AIDS Reagent Program) for 6  h in a final 
Page 5 of 14Ingemarsdotter et al. Retrovirology  (2018) 15:25 
concentration of 100 or 1  µM respectively in triplicate 
wells. After 6  h, 500  µl pLAI-containing supernatant 
at a p24 concentration of 365  ng/ml was added to each 
well, or culture medium was added to control wells. The 
initial drug concentration was thereby reduced by half 
during the infection step and the infection was contin-
ued for 24  h in a final concentration of 50  µM NSC or 
500  nM raltegravir (NIH AIDS Reagent Program). 24  h 
post- infection, cells were harvested by centrifugation for 
5 min at 664×g and the DNA was extracted with DNeasy 
Blood and Tissue kit (Qiagen), according to the manufac-
turer’s instructions with the following minor modifica-
tions; The incubation step with Buffer AL, was performed 
for 30 min at 56 °C, and the DNA was eluted in nuclease-
free water (Thermo Fisher Scientific).
Alu‑Gag PCR
Integrated HIV DNA was amplified with the Alu-gag 
PCR based on a previously published method [20]. 1 μg 
of extracted DNA was used as template in each PCR con-
taining 1× Colorless GoTaq Reaction buffer (Promega), 
100  nM Alu Forward primer: 5′GCCTCCCAAAGT-
GCTGGGATTACA-3′ and 600 nM gag Reverse primer: 
5′GTTCCTGCTATGTCACTTCC-3′ [20] PCR nucleo-
tide mix (Promega) [200 µM], Go Taq G2 DNA polymer-
ase (M7841 Promega) 2.5 U, in a final reaction volume of 
50 µl. Samples were heated to 95 °C for 2 min. The DNA 
was amplified during the 40 PCR cycles as follows: 95 °C, 
15 s; 50 °C, 15 s; 72 °C, 5 min.
The Alu-gag PCR products were purified with the 
QIAquick PCR purification kit (Qiagen) according to the 
manufacturer’s instructions. The purified PCR products 
were eluted in 30 µl nuclease free water (Ambion).
Late RT PCR
Late RT PCR products were amplified by PCR using the 
pR 5′-AGACCAGATCTGAGCCTGGGAG-3′ and pMA’ 
5′-CTGACGCTCTCGCACCC-3′ primers at a final con-
centration of 100 nM for each primer [21]. 400 ng DNA, 
extracted from LAI-infected or uninfected control cells, 
was used as template in each PCR reaction containing 1× 
Green GoTaq Reaction buffer (Promega), 200  µM PCR 
nucleotide mix (Promega), 100  nM pR primer, 100  nM 
pMA’ primer, and Go Taq G2 DNA polymerase (M7841 
Promega) at a final concentration of 1.25 U, in a reaction 
volume of 50 µl. The PCR cycling conditions were as fol-
lows; 95  °C, 2 min; 40 cycles at 95  °C, 30 s; 64  °C, 30 s; 
73 °C, 30 s; followed by 73 °C for 5 min.
HIV‑1 gag PCR
To quantify the amount of integrated HIV-1 DNA, 2 μl of 
the purified Alu-gag PCR products were used as template 
in qPCR in a final volume of 10 µl and subjected to HIV 
gag qPCR as described above with 25  nM HIV gag for-
ward primer and HIV 25  nM gag reverse primer and 
100 nM HIV gag probe. 20–40 ng non-Alu-gag amplified 
DNA template was included as negative control for back-
ground levels.
Beta‑actin qPCR
20  ng of input DNA for the Alu-gag PCR was used as 
template to amplify β-actin with the following prim-
ers: β-actin forward primer: 5′-GAGCGGTTCCGCT-
GCCCTGAGGCACTC-3′ and β-actin reverse primer: 
5′-GGGCAGTGATCTCCTTCTGCATCCTG-3′ at 
40 nM each (final concentration) [22] in a qPCR reaction 
containing 2× Fast SYBR Green Master Mix (Applied 
Biosystems). β-Actin was amplified with the following 
qPCR program on a 7500 Fast Real Time PCR System 
(Applied Biosystems): Step 1. 50  °C for 2  min. Step 2. 
95 °C for 20 s. Step 3. 95 °C for 3 s followed by 60 °C for 
30 s. Step three was repeated for 40 cycles. A dissociation 
stage was included at: 95 °C for 15 s, 60 °C for 20 s, 95 °C 
for 15 s, 60 °C for 15 s.
In vitro dimerization assays
Nucleotides 1–411 of the genome were prepared by 
in vitro transcription using DNA templates and purified 
as described previously [23]. For each sample, 10.5 pmol 
RNA was renatured by heating to 95 °C for 2 min, snap-
cooling on ice for 2 min and diluting to 1 μM in 10 mM 
Tris–HCl, 140 mM KCl, 1 mM NaCl, 1 mM  MgCl2. NSC 
was added at 10× molar ratio either before or immedi-
ately after snap-cooling. RNA was incubated at 37  °C 
for 1–2  h and resolved by native agarose gel electro-
phoresis alongside an RNA ladder (Riboruler low range, 
Thermofisher Scientific) and ethidium bromide stain-
ing. Bands were visualized on a UV transilluminator and 
quantified using Image J software. Each independent 
experiment was performed using a different in vitro tran-
scribed RNA preparation.
SHAPE analysis of RNA
RNA was transcribed and purified as described [23]. 
For each sample, 21  pmol of wild-type or Δp1 packag-
ing signal RNA was renatured by heating to 95  °C for 
2 min, snap-cooling on ice for 2 min and diluting to 1 μM 
in 10  mM Tris–HCl, 140  mM KCl, 1  mM NaCl, 1  mM 
 MgCl2. RNA was incubated at 37  °C for 2  h and each 
sample was divided into two equal volumes. One half 
was treated with a 10× molar ratio of NSC in DMSO 
for 10  min at room temperature (RT) and the other 
received an equal volume of DMSO only. Tubes were 
again divided into two equal volumes before addition of 
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10 mM (final concentration) NMIA in DMSO or DMSO 
only. The RNA samples were purified by ethanol precipi-
tation after 45 min incubation at 37 °C and reverse tran-
scribed as described previously. Samples were analyzed 
by capillary electrophoresis in an ABI 3730 XL sequencer 
and quantified with SHAPEfinder software [19]. Data 
were normalized as described previously [24]. Outliers 
were defined as above and were removed from the data-
set. These constituted less than 8% of values. The aver-
age reactivities were then used as SHAPE constraints in 
RNAstructure [25] to predict structural models and their 
free energies.
Results
Early phases of the viral lifecycle from entry 
through integration are unaffected by NSC
NSC was previously observed to prevent Gag interact-
ing with SL3 in vitro and to stabilize the RNA. Structural 
rearrangement of the RNA, as well as its interaction with 
viral proteins are integral events during reverse tran-
scription [26–28] and potentially vulnerable to an inter-
vention that prevents protein interaction and stabilizes 
SL3 structure. Conceivably a nucleotide binding agent 
might also interfere with the integration step. Perturba-
tion of either of these processes would be detectable by 
infecting NSC treated/untreated cells with wild-type viri-
ons and quantitating integration frequency. Jurkat cells 
were thus pre-treated for 6 h with 100 μM NSC in 500 µl 
medium or untreated, and then mixed with an equal 
volume of medium containing HIV LAI. Viral integra-
tion events were determined by Alu-gag PCR and HIV-1 
gag qPCR, based on a previously described method to 
assay for HIV-1 integration [20]. No statistically sig-
nificant difference in integration events was seen in Jur-
kat cells in the presence of NSC compared to untreated 
pLAI-infected cells 24  h post-infection (Fig.  1). pLAI-
infected cells treated with the integrase inhibitor ralte-
gravir were included as a positive control for inhibition 
of integration, and this led to a greater than 95% reduc-
tion in integration events (p < 0.05 by t test). HIV-1 inte-
gration is thus unaffected by NSC. A similar trend was 
observed in two further independent experiments. As 
NSC is not affecting the levels of integrated provirus seen 
when cells are pre-treated with the compound by impli-
cation it is unlikely that the compound interferes with 
the reverse transcription process, since this should also 
lead to a decrease in the number of integration events. 
We confirmed this by briefly investigating reverse tran-
scription by PCR on extracted DNA using the primers 
pR and pMA’ as previously described [21] to detect late 
reverse transcription products and did not see a change 
in reverse transcription upon treatment with NSC (data 
not shown).
Viral Gag production and budding are not significantly 
affected by NSC treatment
In the previous study ELISA assays on levels of super-
natant p24 suggested the existence of lowered virion 
release from the cell in the presence of NSC. We rein-
vestigated this finding as the previous study did not take 
into account the intracellular p24 levels in each sample. 
Initial ELISA experiments, performed as previously, cor-
roborated an apparent reduction in particle release as 
they showed around a 40% level of p24 in virions puri-
fied from equal volumes of supernatant in the presence 
of NSC versus wild-type. Strikingly this level was similar 
to that seen with the Δp1 virus; both results being sta-
tistically significant to p < 0.05 (Additional file  1). How-
ever, when intracellular p24 production was accounted 
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Fig. 1 Viral integration levels determined in the presence and 
absence of NSC and integration inhibitor. Jurkat cells were pre-
treated with NSC [100 µM] or raltegravir [1 µM], and infected with 
LAI 6 h post-treatment in the presence or absence of 50 µM NSC 
or 500 nM raltegravir. 24 h post-infection, cells were harvested and 
subjected to DNA extraction and HIV-1 integration was assayed by 
Alu-gag PCR followed by quantification of integration events by HIV-1 
gag qPCR. The number of integration events relative to LAI-infected 
cells (WT) in the presence of NSC or raltegravir is shown. For each 
sample, variations in the amount and quality of cellular DNA input 
was accounted for by dividing the number of HIV-1 integration 
events detected by the HIV-1 gag qPCR by the relative actin level 
detected in the input DNA for the Alu-gag PCR. All samples were then 
normalized relative to one another such that the average WT value 
was 1. The average of three samples is shown for each condition. 
Error bars represent SD. *Statistically significant from WT by Student’s 
t test, p < 0.05)
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for (Additional file  1: IC and EC:IC bars) the data were 
no longer statistically significant. As discussed below 
detection of p24 levels depends on effective Gag process-
ing and HIV RNA structure can affect the efficiency of 
viral protease cleavage of the Gag protein during parti-
cle maturation [10, 29]. Accordingly, we also assessed the 
production of Gag protein inside and its export outside 
cells by Western blot in addition to ELISA to ensure that 
we were detecting all Gag protein species regardless of 
their conformation. Using identical preparatory condi-
tions to our qRT-PCR samples, the total amount of Gag 
observed in cellular fractions was measured by densi-
tometry and normalized to GAPDH levels (Fig. 2a solid 
colour bars and Fig. 2b). The amount of Gag present in 
equal volumes of supernatant (Fig.  2a striped bars and 
Fig.  2c) was also measured, and the ratio of extracellu-
lar to intracellular Gag compared (Fig. 2a, spotted bars). 
Figure 2a shows an average of four separate experiments 
each containing 3–4 independent transfections of each of 
wild-type, NSC-treated and Δp1 extracts. No statistically 
significant difference from wild-type was detected when 
assessed in any of these independent experiments by t 
test and, crucially, no trend was apparent either. As levels 
of Gag protein were variable between samples of all three 
types, as can be seen in Fig. 2b, c, we compiled data from 
all four independent experiments to ascertain whether a 
difference would be observed with a larger sample size. 
Again, no significant difference was detected when data 
from all four experiments were compared, as presented 
in Fig.  2a, although on average the relative quantity of 
viral particles in the supernatant after NSC treatment 
was 0.87 of that of wild-type, and 0.65 for SL3 deletion 
virus. This suggests that there may be a small defect in 
particle release upon NSC treatment, and a larger defect 
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Fig. 2 Viral Gag production in the presence and absence of NSC. 293T cells were transfected with HIVΔEnv (WT and NSC) or HIVΔp1ΔEnv (Δp1) 
and VSV-G expression plasmids. 6 h post-transfection, cells were treated with 50 μM NSC (NSC) or the equivalent quantity of DMSO (WT and Δp1). 
24 h post treatment, supernatants and cells were harvested. Equal volumes of samples were electrophoresed on SDS-PAGE gels and immunoblots 
performed using anti-p24/p55 antibody. Cellular blots were stripped and reprobed with anti-GAPDH antibody. a Results of cellular, supernatant and 
supernatant:cellular Gag expression levels, quantified using densitometry. Results show an average of four independent experiments, each contain-
ing 3–6 replicates (with each replicate examining an independently transfected well of a six-well plate) of each experimental condition. b Anti-Gag 
Western blot showing intracellular Gag expression levels, and anti-GAPDH control. Two experimental replicates, from independently transfected 
wells are shown (c) anti-Gag Western blot showing extracellular Gag expression. Two experimental replicates from independently transfected wells 
are shown
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upon SL3 deletion, but that neither of these is statisti-
cally significant using sample sizes of up to 13 replicates. 
Although solution based methods of quantitation are 
often thought to be more robust, the main difference in 
detection mechanism between ELISA and Western blot 
assays is that Western blots analyze all Gag products, 
regardless of their 3D conformation whereas the ELISA 
assay measures the major Capsid protein, p24, in a spe-
cific 3D structure. The ELISA assay may thus be influ-
enced by structural perturbations in the Gag protein, in 
a way that the Western blot assay is not and, in these cir-
cumstances, Western blots provide more accurate data 
on the level of Gag protein released from cells.
In the presence of NSC, the level of viral RNA in the 
cytoplasm is unaffected but levels released into the 
supernatant are reduced
The interaction of Gag with SL3 has been proposed by 
many groups to be important in the packaging process 
[13, 30–32]. In the absence of NSC, Gag protein was 
shown to interact with an isolated SL3 RNA stem loop 
in  vitro causing it to unwind and unmasking a fluoro-
phore attached to the 5′ end from a quencher on the 3′ 
end of the RNA stem-loop. The presence of NSC pre-
vented this unwinding [7, 9]. In a single round infectiv-
ity experiment it led to reduced levels of infectious virion 
production as determined by a Tat-sensitive reporter 
cell-based assay [9]. In order to ascertain whether, by 
preventing the native interaction of Gag with SL3, NSC 
is able to specifically lower gRNA levels inside viral par-
ticles, we measured gRNA levels in cellular lysates and 
purified virions by qRT-PCR in the presence or absence 
of NSC, with the Δp1 virus serving as a positive control 
for inhibition of packaging [13]. Samples transfected with 
pBluescript alone were included as a negative control in 
each experiment and these did not generate a detectable 
signal by qRT-PCR, as expected (data not shown). The 
level of gRNA found in cells was unaffected by the pres-
ence of NSC or by deletion of SL3, as shown in Fig. 3a, 
with no statistically significant differences from wild-type 
observed by t test. However, when the ratio of gRNA 
incorporated into virions was compared to intracellular 
levels a clear reduction was observed in the presence of 
NSC to a similar level to that seen in the SL3 deletion 
virus: Genomic RNA was reduced to approximately 35% 
of wild type levels in the presence of NSC compared to 
34% for the SL3 deletion virus (Fig. 3b). Δp1 results were 
very similar to those observed previously by RPA assay 
[14]. It is possible that these results could reflect a differ-
ence in nuclear RNA metabolism or export, as a quino-
linium derivative such as NSC could conceivably diffuse 
into the nucleus and affect these cellular functions. To 
ascertain whether the decrease in virion gRNA level 
upon NSC treatment we observed was specific to the 
packaging process we performed a nuclear:cytoplasmic 
fractionation and measured cytoplasmic gRNA levels 
against virion gRNA levels by qRT-PCR as before. The 
ratio of virion:cytoplasmic gRNA was 18.5% upon NSC 
treatment and similar to that of the Δp1 virus (22.3%) 
(Fig.  3c), suggesting that the compound acts after the 
cytoplasmic phase of the viral lifecycle.
The greater than five fold reduced level of gRNA in the 
presence of NSC compared to the wild type virus clearly 
cannot be accounted for by the possible minor reduc-
tion in export of Gag. The similarity to the phenotype 
of an established packaging defective mutant supports 
that NSC is primarily an inhibitor of RNA encapsida-
tion. Taken together, these results suggest that NSC is 
specifically lowering the amount of viral RNA inside viral 
particles.
To further confirm this we measured the infectivity of 
virions produced in the presence of NSC. The reporter 
cell line TZMbl was inoculated with equivalent volumes 
of virus-containing medium and the infectivity measured 
compared to WT and Δp1 virus 24  h post-infection by 
luciferase assay. The reduction in infectivity in the pres-
ence of NSC was of a similar magnitude to the reduction 
in gRNA levels detected in virions in the supernatant 
(26% of wt, Fig. 3d). The effect of the drug was to decrease 
viral infectivity to a similar level to that seen in the Δp1 
virus.
NSC does not prevent gRNA dimerization, but does have 
widespread stabilizing effects on the 5′UTR and packaging 
signal RNA structure
gRNA dimerization and RNA encapsidation are inti-
mately linked and interdependent. Although NSC inter-
acts with the loop region of SL3, and SL3 has not been 
implicated as an important component of the dimeriza-
tion process, it is possible that NSC is causing inhibition 
of packaging as a secondary effect by interfering with the 
ability of the viral gRNA to dimerize. In order to ascer-
tain whether NSC acts by preventing dimerization we 
performed in  vitro dimerization assays in the presence 
and absence of NSC. Packaging signal RNA (nts 1–411 of 
the genome) was in vitro transcribed and refolded under 
dimerization inducing conditions as previously described 
[23, 33] and examined by native agarose electrophoresis 
and densitometry. NSC was added either before RNA 
snap-cooling and refolding (data shown in Fig. 4a, b) or 
after snap-cooling and before refolding (data not shown). 
During the in  vitro dimerization process, the formation 
of dimer is a dynamic process, with the amount of dimer 
increasing over time. Thus we also examined dimeriza-
tion at an earlier timepoint, (Fig. 4c) to verify that the lev-
els of dimer that form are changing with time in a similar 
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manner, with or without NSC treatment. No significant 
differences were observed, suggesting that NSC is not 
blocking the ability of the viral RNA to form dimers 
efficiently.
NSC was originally identified as a potential antiviral 
by it inhibiting the ability of Gag to unwind a synthetic 
SL3 RNA molecule. However it was unclear whether the 
major mechanism of action of NSC was prevention of 
Gag binding to SL3, or from prevention of the unwind-
ing of SL3 although there was evidence of the latter effect 
from a rise in melting temperature of SL3 when NSC was 
bound [9]. To further investigate the structural effects of 
NSC on RNA structure of the viral 5′UTR we performed 
SHAPE (selective 2′OH acylation analyzed by primer 
extension) analysis of the dimeric RNA in the presence 
and absence of the compound. SHAPE compounds 
react with the RNA backbone where it is flexible, which 
occurs mainly in single-stranded regions, and are used to 
inform structural modeling. In  vitro transcribed RNAs 
were renatured under conditions that favor dimeriza-
tion, as before. RNAs were treated with NSC in DMSO 
or DMSO only before probing with NMIA (N-methyl 
isatoic anhydride) and fragment analysis as performed 
in previous studies [23, 24]. 12 renatured samples were 
divided into two to be probed with/without NSC and 
divided into two again to be probed with/without NMIA, 
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Fig. 3 Viral gRNA levels analyzed by qRT-PCR, in the presence and absence of NSC. 293T cells were treated as in Fig. 2. 24 h post treatment, super-
natants and cells were harvested, virions purified from 500 μL supernatant and RNA extracted. a gRNA levels in cells, analyzed by qRT-PCR. Each 
sample was first normalized against β-actin levels and then normalized against the average wild-type gRNA levels. Data shown are the average 
of 14 –18 samples taken from four independent experiments. Error bars represent SD. b Ratio of gRNA levels in purified virions from equivalent 
volumes of supernatant to gRNA levels inside cells. Intracellular levels were first normalized against β-actin; these values were then used to divide 
the virion RNA levels for each sample. Data were then normalized against the wild-type average. Data are shown as three independent experiments, 
each containing 4–9 replicates. c Ratio of gRNA levels in purified virions from equivalent volumes of supernatant to cytoplasmic gRNA. Data are 
representative of two independent experiments. d Ability of virions produced in the presence or absence of NSC to transduce cells, measured by 
luciferase assay. Error bars represent the SD. *p < 0.05; **p < 0.01 by Student’s t test. Data are representative of two independent experiments
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using 6 different in  vitro transcription preparations of 
RNA. Data were analyzed with SHAPEfinder software. 
Structures were modeled using RNAstructure [25] and 
are shown in Fig. 5a–d, with numerical data in the Addi-
tional file  2: Table S1. Backbone acylation sensitivity at 
each nucleotide is shown in Fig.  5a for wild-type RNA 
without NSC and for wild-type RNA with NSC in Fig. 5b. 
These data show that the action of NSC on the packaging 
signal RNA structure is to stabilize the sugar–phosphate 
backbone structure, reducing its conformational flexibil-
ity. This is best illustrated by the free energy change upon 
NSC treatment (− 155.3 to − 165.3 kcal/mole). Although 
most acylation differences upon NSC treatment are 
small, the vast majority of nucleotides are less reactive to 
NMIA after NSC treatment, and this extends across the 
RNA, as is shown in Fig. 5c, which illustrates the reactiv-
ity differences before and after NSC treatment. This sta-
bilization occurs at SL3 in particular, as shown in Fig. 5d 
by the larger reduction in SHAPE reagent acylation of 
five of the SL3 nucleotides, but additional effects can be 
seen extending across the entire psi region. To ascertain 
whether these results were due to off-target, nonspecific 
effects of NSC binding to other regions of the RNA, we 
repeated the SHAPE experiments using the Δp1 RNA, 
with and without NSC treatment. This RNA has a 19 nt 
deletion at SL3, but is otherwise isogenic. In contrast to 
the wild type RNA, NSC did not stabilize this transcript 
(Additional file 3: Fig. S2; Additional file 2: Table S1). This 
implies that the stabilization of SL3 is responsible for a 
propagated increase in structural rigidity rather than 
NSC being a non-specific RNA stabilizing agent.
Discussion
We investigated the ability of NSC to block HIV-1 rep-
lication, focusing on individual life cycle stages. When 
virus is produced in the presence of NSC, this RNA-
binding compound specifically reduces the amount of 
gRNA in virions in the supernatant fraction, compared 
to the amount of gRNA available for packaging in the 
cells. This is possibly associated with a non-significant 
minor decrease in the amount of Gag protein detected in 
the supernatant in the presence of NSC. The dominant 
mechanism of action of NSC is to specifically prevent 
the incorporation of viral gRNA into virus particles with 
a comparable defect to that produced in an established 
packaging defective viral mutant, the Δp1 virus. The 
infectivity of the virions produced upon NSC treatment 
correlated well with the reduction in gRNA packaging. 
No effects were seen on other stages of the viral lifecycle 
again confirming that NSC has a specific mechanism of 
action at the packaging stage of the viral lifecycle.
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We cannot fully exclude that equal amounts of gRNA 
are initially incorporated into virions but that NSC 
renders the particles less stable, and they disintegrate 
faster. Although possible, we think this explanation 
is less plausible, as a previous study using a SL3 dele-
tion virus showed no reduction of p24 protein in the 
5’ 5’
-155.3 kcal/mol
0.3 0.5 0.70.9
SHAPE reactivity
3’ 3’
-165.3 kcal/mol
3LS3LS
not determined
C
U
CU
GA
a b
c d
>0.1 units higher acylaon when NSC present
>0.1 units lower acylaon when NSC present
5’ 3’5’ 3’
higher acylaon when NSC present
lower acylaon when NSC present
A
U
SL3 SL3G
G
G
G
G
U
U
U
U
U
U
C
C
C
C
C
A
A
A
G
G
G
G
G
U
U
U
U
U
U
C
C
C
C
C
A
A
A
not determined not determined
A
Fig. 5 Structural effects of NSC on the gRNA. The first 411 nts of the gRNA, containing the packaging signal region and beginning of the gag ORF 
were in vitro transcribed and refolded. RNA was treated with NSC in DMSO or DMSO only. Acylation sensitivity at each nucleotide was used to 
model the structure and predicted free energy. The most stable structure is shown. a Predicted RNA structure and stability of DMSO treated RNA. 
b Predicted RNA structure and stability of NSC treated RNA. c, d Acylation sensitivity difference upon NSC treatment. c Differences > or < 0 and d 
differences > or < 0.1 reactivity units
Page 12 of 14Ingemarsdotter et al. Retrovirology  (2018) 15:25 
virion- associated fraction, versus wild-type virus [34]. 
It is also possible that NSC does not prevent the initial 
stages of packaging, but instead destabilizes the RNA 
inside virions, leading to degradation of the RNA. In 
practical terms the effect is the same and gRNA levels in 
virions are lowered, which would be an equally desirable 
therapeutic outcome.
Our findings are summarized schematically in Fig. 6.
We observed that ELISA and Western blot can give 
differing results for Gag protein levels in the presence of 
RNA binding agents or RNA structural deletion mutants. 
These findings resonate with the known effects of RNA 
on structural stability of HIV virions [35] and may pos-
sibly relate to effects of RNA on Gag processing [36]. 
This observation has implications for investigation of 
viral processes that involve different structural changes 
in Gag and suggests that results should be validated by 
Western blots, or by alternative analyses relying on quan-
tification of denatured proteins rather than relying only 
on methods detecting the native state. This is particu-
larly pertinent as the viral maturation process involves 
multiple cleavages and structural rearrangements of the 
Gag protein, such as the formation of a new beta-hairpin 
structure in CA, necessary for proper core formation 
[37, 38]. Although large and small-scale structural rear-
rangements of the Gag polyprotein have been proposed 
to occur [38, 39] little is known about the structures of 
the cleavage intermediates. In addition, incorrect cleav-
age order has been shown to affect the viability of virions 
[40, 41].
HIV-1 RNA has been suggested to adopt a range of 
different conformers, with each one playing a different 
role in the viral lifecycle [10, 42, 43]. The SHAPE data 
presented here illustrate that NSC not only enhances 
the stability of SL3 but that this also stabilizes the entire 
packaging signal region, reducing its conformational flex-
ibility. This result suggests that by stabilizing SL3, the 
‘BMH’ form [44] of the RNA is stabilized. In this way, a 
structural stabilization at one site propagates across the 
structure, having wide-reaching effects. Acylation sensi-
tivity differences within single-stranded regions are likely 
to be due to stabilization of the backbone into more or 
less reactive noncanonically paired conformations, such 
as by differences in sugar-pucker or noncanonical inter-
actions [45]. Recent publications indicated that although 
TAR-binding compounds had small longer-range struc-
tural effects outside TAR [46, 47], they did not have such 
far-reaching stabilizing effects. The structure of SL3 is 
usually similar between structural models of the HIV-1 
leader region produced by different groups [48–50] and 
it has not been proposed to be an integral part of confor-
mational switches in the viral RNA. However, the stabi-
lization of a BMH-like structure by NSC binding to SL3 
suggests that unwinding or stabilization of the SL3 site 
may play a pivotal role in controlling structural changes 
within the HIV-1 leader RNA.
SL3 has recently been proposed to be of lower impor-
tance for Gag binding and viral packaging than nearby 
motifs [51], however, we show here that a compound that 
specifically binds to it has reasonably large effects on viral 
Fig. 6 Schematic diagram showing the RNA packaging impairment upon NSC treatment. NSC may also be present inside virions
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packaging efficiency, making a case for its importance in 
the packaging process.
Interestingly, our findings indicate that an HIV-1 RNA 
which is stabilized at SL3 does not show defects at other 
stages of the lifecycle, suggesting that structural flexibility 
imparted by this region is not necessary for other lifecy-
cle stages.
Although our results show that in vitro, NSC does not 
influence the ability of the viral RNA to form dimers, we 
cannot exclude that it affects the structure or the dynamic 
stability of the dimers that do form in  vivo. A recent 
model suggests that it is not simply SL1 that remodels 
into an intermolecular duplex, but also extensive regions 
around SL1, including the U5:AUG interaction, which 
was previously thought to be intramolecular [52]. SL3 is 
positioned in the middle of this proposed intermolecular 
interaction and its remodeling may be important for for-
mation of the extended intermolecular complex.
Conclusions
By binding to the SL3 RNA in ψ, NSC specifically inhib-
its the incorporation of HIV gRNA into virions. It does 
this without affecting earlier processes of the viral life-
cycle such as reverse transcription, integration, produc-
tion and nuclear export of viral gRNA or the steady-state 
intracellular Gag protein levels. NSC260594 is thus a 
first-in-class RNA-binding anti-packaging compound. As 
a small molecule that affects RNA structure and function, 
it can be used to interrogate the role of RNA structure 
in the viral lifecycle without the need for mutation of the 
viral genome.
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